MEDIF Stock Chart & Stats
$0.06
>-$0.01(-5.26%)
At close: 4:00 PM EDT
$0.06
>-$0.01(-5.26%)
Day’s Range― - ―
52-Week Range$0.04 - $0.08
Previous CloseN/A
Volume23.34K
Average Volume (3M)43.16K
Market Cap
$21.00M
Enterprise Value$20.36
Total Cash (Recent Filing)$9.85M
Total Debt (Recent Filing)$421.00K
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Nov 16, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding427,177,150
10 Day Avg. Volume42,056
30 Day Avg. Volume43,158
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$28.34M
Bulls Say, Bears Say
Bulls Say
Operational Profitability RecoveryReturning to quarterly profitability and sustaining positive adjusted EBITDA indicate meaningful operating recovery rather than isolated cost cutting. If maintained, stronger margins and lower expenses can improve earnings quality, support reinvestment, and move the business toward durable self-funding.
Low Leverage And Asset BackingA cash-rich balance sheet with virtually no debt reduces solvency and refinancing pressure while the company executes its turnaround. Facility ownership also provides operating capacity and asset support, giving management more flexibility to fund regulated-market growth without relying heavily on borrowing.
International Medical GrowthInternational medical growth is expanding both revenue and geographic reach, with Germany demonstrating strong demand momentum. A broader regulated-market footprint can diversify the business, deepen customer relationships, and create a platform for additional shipments and replenishment orders over subsequent quarters.
Bears Say
Persistent Unprofitability And Cash BurnDespite recent quarterly improvement, the trailing business remains unprofitable and does not yet generate positive operating or free cash flow. Continued cash burn can constrain investment capacity and increase reliance on liquidity management until margin gains translate into consistently positive cash conversion.
Canadian Medical Reimbursement PressureThe VAC reimbursement reduction directly pressures pricing and revenue in a medical channel that previously contributed meaningful sales. Mitigation through cost, supply-chain, and product-mix actions may help, but the policy change can weigh on Canadian medical revenue and margins over the coming quarters.
Exposure To Regulatory And Channel ConcentrationHeavy reliance on international and medical revenue concentrates results in jurisdictions governed by changing reimbursement, prescribing, and regulatory regimes. This exposure can make revenue less predictable and amplify the effect of policy changes, even as the company expands its regulated-market presence.
MediPharm Labs News
MEDIF FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was $0.04 and its highest was $0.07 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is $21.00M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Nov 16, 2026 which is in 46 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on Aug 13, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.002 by $0.002.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 427,177,150 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of $0 in its last earnings report, beating expectations of -$0.002. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in MEDIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across Canada, Australia, Germany, and other international territories. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations. Furthermore, MediPharm Labs provides auxiliary services including GMP-certified flower procurement, specialized packaging, and comprehensive logistics. This enterprise was established in 2015 and has its corporate headquarters situated in Barrie, Canada.
MEDIF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial recovery: return to profitability, highest adjusted EBITDA since 2019, robust margin expansion, meaningful sequential revenue growth driven by international markets (notably Germany), successful Phase II LiBBY clinical results validating the pharmaceutical platform, and balance sheet strength. Headwinds include a material 30% VAC reimbursement cut that reduced Canadian medical revenue, ongoing pricing pressure and competition in key markets (Germany), and broader prescribing/reimbursement uncertainties. Overall, the positive operational execution, clinical validation, and improved profitability notably outweigh the identified challenges.View all MEDIF earnings summaries